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Background: Aminoglycoside antibiotics interfere 
with ribosomal protein synthesis and with intron splic- 
ing.Various lines of evidence suggest that RNA is the 
molecular target for aminoglycosides, but little is 
known about the recognition process. Is recognition of 
a particular aminoglycoside specific for certain RNA 
structures? If so, what are the rules for recognition? 
We have begun to investigate this problem by in 
vitro selection of RNA molecules that can specifically 
bind to the aminoglycoside antibiotic tobramycin. 
Results: An RNA diversity library was used to select for 
sequences capable of binding to the aminoglycoside anti- 
biotic tobramycin.After six cycles of selection, 82 % of the 
RNA bound to tobramycin specifically. The selected 
RNA was reverse-transcribed into DNA, which was then 
cloned. At low selection stringency, an extremely large 
number of clones, on the order of 107, produced RNAs 
capable of binding tobramycin with Kds in the PM range 
(values similar to that observed for the binding of 
tobramycin to Escherichia coli ribosomes). Sequencing of 18 
of the clones revealed no obvious consensus sequence. At 
higher selection stringencies (Kds in the nM range) only 
two consensus sequences for binding were observed. 
Conclusions: We have shown that RNA molecules 
can be readily selected that bind the aminoglycoside 
tobramycin.The RNAs that bind tobramycin with high 
affinity contain consensus binding regions that may be 
confined to predicted stem-loop structures. These 
studies open the way for understanding the basis of 
RNA-aminoglycoside recognition. 
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Introduction 
Antibiotics that interfere with protein synthesis often 
bind to ribosomal RNA (rRNA) rather than to ribo- 
somal proteins. Substantial evidence in support of this 
view has been reported. Resistance to various antibiotics 
often involves methylation at specific sites in rRNA [l]. 
The antibiotic thiostreptone binds tightly to a 60- 
nucleotide sequence (60-mer) from rRNA [2]. 
Aminoglycosides and peptide antibiotics can inhibit 
group I intron splicing by binding to specific regions of 
the RNA [3,4]. Certain aminoglycosides and other 
protein-synthesis inhibitors have also been found to 
interact with specific bases in 16s rRNA [5]. 
Interestingly, a molecular basis for hypersensitivity to 
aminoglycosides has been localized to a single base 
change in mitochondrial rRNA [6]. Along these lines, 
an oligonucleotide analog of the 16s rRNA has also 
been shown to interact with certain aminoglycosides 
[7]. It has been suggested that there may be common 
features in the modes of recognition of aminoglycoside 
antibiotics with self-splicing introns and with the 
decoding regions of 16s rRNA [8]. Recent studies have 
also shown that aminoglycosides can bind to a hammer- 
head ribozyme [9] and can also block the binding of the 
HIV Rev protein to its viral RNA recognition element 
[lo]. While these kinds of experiments implicate RNA 
as the target for various antibiotics, including the 
aminoglycosides, there are no reports demonstrating the 
specific binding of any aminoglycoside to a particular 
domain of an RNA molecule. 
From the observations described above it is probable 
that rRNA is a target for many of the antibiotics that 
inhibit protein synthesis. This notion is consistent with 
the chemical properties of the antibiotics and rRNA. 
For example, the aminoglycosides, which are a particu- 
larly well studied and important group of antibiotics, are 
polycationic saccharides at neutral pHs and would be 
expected to interact effectively with RNA both through 
electrostatic interactions and through hydrogen 
bonding. It would be of substantial interest to determine 
what kinds of RNA structures are recognized by mol- 
ecules like the aminoglycosides. Are the numbers of 
such structures limited, and if so what are they? 
To address these issues, we have begun to explore the 
use of in vitro selection of aptamers from RNA diversity 
libraries [l l-131 to define the kinds of RNA molecules 
that bind to a particular aminoglycoside, in this case 
tobramycin. Figure 1 shows the structures of tobramycin 
and its analogs, 6’-N-acetyl tobramycin and 6’-N-4- 
pyrenebutyryl tobramycin. Tobramycin has practical 
advantages for these kinds of studies, because it can be 
specifically acetylated at the less hindered 6’ primary 
amino group to provide useful analogs for molecular 
studies [14,15]. Moreover, the acetylated tobramycin 
analogs that have been tested retain biological activity 
[15]. In this article we show that an assortment of RNA 
molecules that can be selected from a random RNA 
pool can specifically recognize tobramycin. Selections 
were performed using a tobramycin affinity column at 
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Fig. 1. Structures of tobramycin and analogs used in these studies. 
different densities of the coupled drug. Binding was ana- 
lyzed with PYT (Fig. l), a pyrene-butyramide-labeled 
fluorescent derivative of tobramycin. 
Selections were initially performed at low stringency. 
The K, for tobramycin binding is 4.3 FM, and that for 
PYT is 200-fold less (20 nM) for one particular RNA 
molecule selected at this stringency with one 
tobramycin binding site per molecule. By using the 
fluorescence assay it was also determined that, overall, 
the pool of RNAs selected at low stringency binds 
PYT with a K, of 52 & 8 nM, and tobramycin with a 
K, of 8.8 & 0.3 FM. When selections were performed 
at higher stringencies, tighter binding RNAs were 
found, containing one of two consensus sequences. 
These consensus sequences were confined to predicted 
stem-loop structures, as demonstrated by independent 
synthesis. The binding of tobramycin to these aptamers 
proved to be in the nM range. These data show that 
tight-binding RNA molecules can readily be selected 
for aminoglycoside antibiotics. Moreover, as the strin- 
gency of selection is increased the number of RNA 
molecules capable of binding to aminoglycosides radi- 
cally decreases. Structural studies on the selected RNA 
molecules should shed light on the rules that govern 
specific aminoglycoside-RNA binding interactions. 
Results 
Selection of RNA molecules that bind to 
immobilized tobramycin 
Initial studies were focused on the interaction of the 
random RNA pool with the tobramycin affinity 
column described below (see Materials and methods). 
This column was prepared using 20 I_cmoles of 
tobramycin to couple to 15 kmoles of N-hydroxysuc- 
cinimide-reactive sites per ml on the column. This ‘low 
stringency’ column was used in the initial selections to 
obtain as many sequences as possible that could recog- 
nize tobramycin. The randomized pool consisted of 
109-mer RNA transcripts containing 60 central ran- 
domized bases flanked by PCR primer sequences con- 
taining a T7 RNA polymerase promoter.This pool of 
RNAs was transcribed from a pool of aptamer DNA 
plasmid constructs, designed as previously described 
[16]. The original 32P-labeled RNA pool was pro- 
duced by transcription of 120 p,g of the DNA pool. 
Elution patterns of the RNA from the columns are 
shown in Figure 2 for the second and sixth selections. 
Over six cycles of selection, the percentages of RNA 
specifically eluted with 10mM tobramycin were 
~0.1 %, 3.0 %, 2.9 %, 26 %, 55 % and 82 %. Further 
selections did not increase the specific binding pool. 
The RNA pool transcribed from DNA after the sixth 
selection could not be eluted from the affinity column, 
even after 100 column volumes of selection buffer 
were passed through the column. Furthermore, 10 
column volumes of selection buffer containing 50 mM 
D-glucosamine did not cause any bound RNA to be 
eluted from the column, while 96 % of the RNA 
could be eluted with three column volumes of 10 mM 
tobramycin. The observation that D-glucosamine did 
not cause the elution of the bound RNA suggests that 
the binding interaction is specific. 
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Fig. 2. The elution profiles for cycle 2 (+) and cycle 6 (0) of the 
low-affinity aptamer selection. After the tobramycin affinity 
column was washed with 20 column volumes of selection buffer, 
bound RNA was specifically eluted with 10 mM tobramycin in 
selection buffer. 
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1. 5’... AAUUGGAUCAUACUGUUAUAAGUAGGUGGCUCAGCGGUUGCCUUCGGCAGGUUGAUCCGU...3' 
2. 5'... GUGGUAUAUCCUGGUUGUGCGUAUGUACUCCGGCUUCUAUAGUUCUGGUUGGUGGCGGAC...3' 
3. S'... UGUGAUAGGACUGUGAUUCGGAUCAUGUUGUGAACAUGGUGUGCAUCAUGGGGAGCCCGU...3' 
4. 5'... CUCAUUCACGGGAUGGCUCUUACACAGUCUGUGUAGGGCGUCGCGUGUGGUUAUGUUGG'C...3' 
5. 5'... UUCACGGCAUAAUUCUGUUUGAGUUGGCCUUUUGGUAAUGUAGCGUGGGUUUGCGGUGCG...3' 
6. 5's.. CCUGUGGGGCGUACGUUGGUACAAGAGGUUAGGUGGCCUAAUGUAGCCUACGUGCGGCGU...3' 
7. S'... CUGCUGCAGUUGUUAUGGGCCGUUCUAACUGGGGUGGUACCCGACCGAGUCAGCAGGUG....3' 
8. 5'... CGUUUGGGGUCCCACAACACAGGUCUUUGCUGGUCAUAUAUGCGUGUCCUCUAGGAAGUG,..3' 
9. 5'... CGUAAAUGGCGCAACGUCGCUCAUGUCGGGUUGGCCAAGUUUCAUUUGCGUUGUCUCAGU...3' 
IO. 5'... GGCGUUCAGCGGUUCUUCGGGUAAGGCCGUGAGUGUGCGUACGUGAGGGUUAACGCCGU....3' 
11. 5’... UAUGUUGCACCCACUGCGGUUCAGUUAUGGUUGUUUCGGCCAUUUGGUUCGCAGCUGUGA...3' 
12. 5'... GGUCAGGCGUCUCAUGUAGUUUGUUCCUGUGUAUAUUUGCUCUCUUCGGGGACACCCUGUC..3' 
13. 5'... AGUGAUUAUCACAACAGUAUGUCUGGUUGCUCAUGGAGGUUGCAUUGAGGCUAUUAGUAG...3' 
14. 5'... UCAAGUCCUGUCUGGUGCGCCUACAGGAUUGGGAUCAUGGGUGUCAAGCAUUUGUGUC.....3' 
15. 5'... CACGGUAAAGUAGCAUUGUUCGUUUCCUUGUUUUACUACUCGUAGUGACAGCAGAUGCUG...3' 
16. 5'... UGUGUUGCUACGAGGUUGGCCAAUAUGUAGCGUUGCUGCAUAGUGGUUGUCUUAUAUCUG...3' 
17. 5'... UGCAGGCUUUUGGCUGUGGGUUUAUGUCCAUGUGUUAGAUCAGCGUUUUACGGUUAGCGC...3' 
18. 5'... CCACUAGGCUACAUAGGCGUACAUCCUUCCCGGAGGUCUUAGCGCCGCUAUGGGGUUGGA...3' 
Fig. 3. Nucleotide sequences ot low-attinity aptamers.The sequence ofthe random region of18 clones is shown. Total sequence: 
5'.GGGAGAAUUCCGACCAGAAGCUU-random region-CAUAUGUGCGUCUACAUGGAUCCUCA-3'. 
Cloning and sequencing of the selected pool 
RNAs &ted after the sixth round of selection were 
reverse-transcribed and cloned. We sequenced 18 of the 
clones to determine if there were consensus sequences. 
As can be seen in Figure 3, no obvious consensus 
sequence was observed. 
We investigated 10 RNA aptamers (clones l-10) pre- 
pared from these clones and showed that they bound 
specifically to the affinity column, as they could not be 
eluted with more than 100 column volumes of selection 
buffer, but were eluted with 3 column volumes of selec- 
tion buffer containing 10 mM tobramycin. 
Wavelength (nm) 
Fig.4. Fluorescence emission spectra of PYT solution in the pres- 
ence of varying concentrations ofW13 RNA. [PYT] = 151 nM. 
[W13-RNA]: 1, 0; 2, 0.056 PM; 3, 0.112 FM; 4, 0.224 FM; 5, 
0.44 FM; 6, 0.7 +M; 7, 1.1 FM. 
Dissociation constant measurements on an aptamer 
One of the clones (shown as clone 8 in Fig. 3; henceforth 
referred to as W13) was chosen for quantitative studies to 
determine the specificity of its binding to tobramycin. 
Using equilibrium dialysis, the K, for 3H-acetyl 
tobramycin (Fig. 1) was determined to be 1.3 PM. The 
K, for tobramycin was determined to be 3 FM by com- 
petition studies with 3H-acetyl tobramycin. These values 
are close to those measured for tobramycin and 3H-acetyl 
tobramycin binding to ribosomal targets [15]. 
Equilibrium dialysis measurements are not well suited 
for detailed studies on tobramycin binding, because of 
practical limitations in the available specific activity of 
the 3H-acetyl tobramycin. To study the binding behavior 
ofW13 carefully, the fluorescently labeled pyrene conju- 
gated tobramycin derivative PYT was prepared (Fig. 1). 
Pyrene derivatives are useful for studying RNA interac- 
tions, as the fluorescence intensity can be markedly 
affected by binding to RNA [17,18]. In the present case, 
the fluorescence emission intensity of PYT proved to be 
strongly quenched upon addition ofW13 RNA (Fig. 4), 
indicating complex formation between the RNA and 
the ligand.The very large dynamic range (>lO) observed 
here makes careful quantitative studies on binding possi- 
ble. The fluorescence intensity of PYT as a function of 
RNA concentration fits an equation for a 1:l complex 
(see Materials and methods) very well, as shown in 
Figure 5, giving a K, = 20 & 4 nM. This means that 
there is a tight 1:l complex formed between the anti- 
biotic and RNA. Competition experiments show that 
tobramycin competes with PYT for binding to the 
RNA (Fig. 6). Curve fitting using the fluorescence 
intensity of PYT as a function of the tobramycin con- 
centration gave a K, = 4.3 + 0.7 FM for tobramycin 
(Fig. 7).Therefore PYT binds to W13 > 200 times more 
tightly than does tobramycin itself. Other antibiotics and 
glucosamine were also tested for their abilities to bind 
specifically to W13 RNA. As can be seen in Table 1, 
glucosamine does not bind, and erythromycin binds 
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Fig. 5. Fluorescence titration of PYT as a function of WI 3 RNA 
concentration. The solid line is calculated using Equation 1 
described in Materials and methods (curve obtained by 
curve fitting). 
relatively weakly. On the other hand, the aminoglycoside 
antibiotics gentamycin and in particular neomycin, both 
of which are structurally related to tobramycin, bind 
well to W13 RNA. 
The results described above demonstrate that one of the 
selected clones can bind to tobramycin with a relatively 
high affinity. It is possible that we were just fortunate in 
choosing this clone.To address this issue, the average K, 
values for the selected random pool was measured. Using 
Wavelength (nm) 
Fig. 6. Fluorescence emission spectra of PYT solution containing 
WI3 RNA in the presence of varying concentrations of 
tobramycin. [PYT] = 152 nM. [WI3 RNA] = 300 nM. 
[Tobramycin]: 1, 0; 2, 0.73 yM; 3, 2.57 t.r,M; 4, 10.06 PM; 5, 
44.86 p,M; 6, 81.39 FM; 7,264.85 PM; 8,631.76 /.LM. 
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Fig. 7. Fluorescence titration of PYT solution containing WI3 
RNA as a function of tobramycin concentration. The solid line 
is calculated using Equation 2 described in Materials and 
methods (curve obtained by curve fitting). 
the fluorescence assay we found that, overall, the selected 
pool mixture binds PYT with a K, of 52 f 8 nM, and 
tobramycin with a K, of 8.8 & 0.3 PM (data not 
shown).Therefore, the clone chosen for analysis (W13) is 
representative of the average binding capacity of the 
selected random pool. 
Reselection for higher affinity aptamers 
While the average K, for the previously selected RNA 
pool is in the PM range, it is likely that there are also 
higher affinity aptamers in this mix that are infre- 
quently represented in the pool.The fact that no con- 
sensus sequence was observed in the previous selections 
shows that the selected pool is not close to exhaustion 
with respect to tobramycin-binding aptamers. A new 
Affi-Gel was prepared using 0.075 pmoles tobramycin 
per ml of gel in the coupling reaction instead of 
20 kmoles tobramycin per ml of gel. The RNA pool 
that was obtained after the sixth cycle of the first selec- 
tion was reselected against this new gel. Over seven 
cycles of selection, the percentages of RNA specifically 
eluted with 10 mM tobramycin were 0.3 %, 4.9 %, 
6.6 %, 21.9 %, 9.1 %, 50.7 % and 86.1 %, for a total 
amplification of -1.2 x 107. When RNAs from this 
selected pool were cloned and -40 of the clones were 
Table 1. Dissociation constants of W13 RNA to antibiotics. 
PYT 0.02OztO.007 
Tobramycin 4.3+0.7 
D-Glucosamine N.B.* 
Erythromycin 505+25 
Gentamycin C 47211 
Neomycin B 4.7+0.9 
Binding was determined at 20 “C. o-Glucosamine was used as 
a control for non-specific binding. *N.B., no detectable binding. 
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X1(4): 5’... CUGGUUAGUUUUGCACAGUGGTCGAUGCUAGACU~~G~~~~GG~~~~AGUCCAAUAGUC...3’ 
’ _i, a, 
X8(2): 5’... GCGGUUGAGCGCUCCGGUACAUUGACAGGCAGGCAU’~~U~~AAC~~~~~~UGCUUGGACUU...3’ 
K13Cl): 5’... CUG’6sdd~KGG~A~‘O(jAGCAUCAUCGGCCGAUUUCAUCUCUGUGGGUAGUACGGAAGCAC...3’ 
-~~~-~~~-~~~-~~---~---~---~---~---~_ 
J6C13): 5’... 
: W&i ~+~*‘~W,~W; 
AGUAUAGCG~~~~~:!~~,G~~~~~~~CGUGCUGAUCGUUUGGUACGGGACCUGCGUGUAGCC . . .3’ 
J14(2>: 5’... CCAAAAAAGUAAGGACGAGAGCCG’ACU~~~~~~~G~~~~~~~AGAGCUCUCCGCCAACGG...3’ 
X3(8): 5’... UGGUUGUCUUGUACGUUCACUGUUACGAUUGUGUU’~~~~~A~~~~~~~UUGCAAUCG....3t 
Fig. 8. Nucleotide sequences of high-affinity aptamers. Six independent sequences are shown with the number of times that each 
sequence was obtained indicated in parentheses. The sequences fall into two groups. Consensus sequences are highlighted. 
sequenced, two clear consensus sequences, highlighted 
in Figure 8, were observed. The consensus sequences 
fall into two groups, which show substantial homology. 
In addition, some of the sequences were found to be 
present in many different clones.This shows that there 
are only a few solutions to generating high-affinity 
binding RNA molecules directed towards tobramycin. 
Furthermore, this result is also consistent with expecta- 
tions based on the amplification factors observed in the 
two selections.After starting with lOI RNA molecules 
and selecting 1:107 in two rounds of amplification, one 
would expect that there should be only 10 high-affinity 
sequences in the starting material. 
The binding of tobramycin to two cloned RNAs (Xl 
and J6, Fig. 8), representing each class of consensus 
sequences, was measured using the fluorescence tech- 
niques already described (Table 2). As expected, the 
binding of tobramycin to both RNAs (Xl and J6) was 
of high affinity. However, in these cases two molecules 
of tobramycin are bound to each RNA molecule; one 
tobramycin molecule binds specifically in a high-affinity 
mode and the other binds specifically in a low-affinity 
mode. A saturation binding curve showing the biphasic 
binding behavior ofJ6 RNA is shown in Figure 9.The 
high-affinity component binds tobramycin lo3 times 
more tightly than do sensitive ribosomes [15]. 
The consensus sequences determined for the two groups 
of high-affinity binding RNAs probably form part of the 
tobramycin-binding region. Accordingly, we would 
expect that these sequences would be found in non- 
base-paired regions of the RNA. RNA secondary struc- 
ture analysis of the two RNA molecules, using the 
program MFOLD [19], indicates that this indeed may be 
the case. Two representative lowest energy structures are 
shown in Figure 10, illustrating that the consensus 
sequences exist in stem-loop structures. The predicted 
stem-loop structures of both Xl and J6 were prepared 
with extra GC base pairs to secure the stem-loop struc- 
ture. As expected, analysis of these minimal RNAs by 
MFOLD generated the structures shown in Figure 10. 
Both minimal stem-loop structures bound tobramycin 
with high affinity (Table 2) and with the same 2:l stoi- 
chiometry that was observed with Xl and 56. Thus, the 
tobramycin binding sites of Xl and J6 are probably 
located in the stem-loops. It should be noted that, in the 
case of the Xl stem-loop, the shorter chain analog of 
PYT (6’-N-4-py reneacetyl tobramycin), was required to 
give quantitatively useful fluorescence quenching. 
Discussion 
One approach to exploring the rules that govern 
RNA-antibiotic interactions is first to determine if 
particular RNA molecules can be selected that bind 
specifically to certain antibiotics, then determine the 
structures of these complexes. We have selected RNA 
molecules that can bind to the aminoglycoside 
tobramycin with high affinity. Although less than 0.1 % 
of the total RNA applied to the initial tobramycin 
affinity column was specifically eluted with tobra- 
mycin, the specific binding pool could be increased to 
82 % after six cycles of selections. It can be calculated 
that the experiments began with at most -lOI 
sequences. The six cycles of selection amplified the 
tobramycin-binding aptamers by a factor of -107, 
leaving a maximum of -lo8 sequences that can bind 
tobramycin with a K, in the iOp,M range. In practice, 
it would be expected that the functional diversity of 
this pool is probably reduced by .a factor of -10 due to 
Table 2. Dissociation constants of RNA aptamers. 
J6 Xl J6sl Xlsl 
K,WT) (nM) 5.4+0.5a 7.6kl .l a 286~1 Oa 65.1 +7.4b 
K, (TOB) (nM) 2kl 3&l 9k3 12+5 
K,(TW ($W 6.020.4 15.920.7 2.7kO.3 13.2*0.5 
Binding measurements were made at 20 “C as described in Materials and methods. The high affinity component for aPYT, or 
b6’-N-4-pyreneacetyl tobramycin, is measured along with both high- and low-affinity components (K, and K,, respectively) for the 
binding of tobramycin (TOB). Values for binding to 16, Xl and their stem-loop (sl) counterparts are given. 
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Fig. 9. Fluorescence titration of PYT 
solution containing J6-RNA as a func- 
tion of tobramycin concentration. 
[PYTI = 15.0 nM, [J6-RNA] = 35nM. 
Tobramycin binds to J6-RNA in high 
and low affinity modes. The insert 
shows the high affinity binding in an 
expanded scale. 
limitations in the chemistry of oligomer synthesis. So it 
is likely that there are in the neighborhood of lo’-lo* 
RNA sequences in the selected pool that can bind 
tobramycin.This is interesting because it suggests that 
there are many different ways for an RNA molecule 
to recognize an aminoglycoside with a moderately 
high affinity. 
The DNA from reverse-transcription of the random 
aptamer pool was cloned in order to analyze individual 
sequences. Plasmid DNA from 18 clones was sequenced. 
No two of the sequences were identical, and no consen- 
sus sequence was observed. The great diversity of the 
pool is reflected in the observation that the 18 
sequences cloned were all unique. It is clear that RNA 
structures can be organized in many different ways to 
recognize tobramycin with p,M affinity. Of course it is 
possible that many of these RNA structures are similar 
in local structure. Since tobramycin is polycationic at 
the pH studied, electrostatic interactions between the 
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Fig. IO. Minimized structures for Xl, J6 
and corresponding stem-loops. 
Outlined areas indicate consensus 
regions. The stem-loops are con- 
structed with extra G-C base pairs to 
secure the structures. The bold dots 
indicate wobble base pairs and the 
small dots in the outlined areas 
indicate non-consensus bases. 
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drug and RNA, along with hydrogen bonding, are 
probably important in mediating recognition.This being 
the case, base-sequence specificity pev se would not be 
expected to be of overriding importance, because 
tobramycin is unlikely to be recognizing specific 
sequences of nucleotides. 
The RNA from this combined pool exhibited an 
average K, for tobramycin of -8.8 pM.This is an inter- 
esting result, because this is close to the K, measured 
for the specific binding of tobramycin to sensitive ribo- 
somes [15]. From the studies reported here, there are 
clearly many RNA sequences that bind to tobramycin 
with K, values in the p,M range. Why there might be 
such a limited number of specific tobramycin binding 
sites in ribosomes is understandable in terms of the 
possible RNA diversity in cells. It must be remembered 
that, in the work reported here, only one RNA 
sequence in -lo7 sequences can bind tobramycin. 
Although it is clearly impractical to study the specificity 
of binding of all of the clones quantitatively, we did study 
one clone (W13) in some detail. Equilibrium dialysis 
showed that the K, of W13 for acetyl tobramycin was 
1.3 PM and that for tobramycin was 3.0 PM. These 
values are close to the K,s of these compounds measured 
for ribosomes.The measured K, for the binding of acetyl 
tobramycin to E. coli ribosomes is 3.3 FM, and that for 
tobramycin itself is 1.1 FM [15]. 
To better assess the specificity of tobramycin binding to 
W13 RNA, a fluorescence protocol using PYT was 
developed. The fluorescence emission intensity of this 
probe was strongly quenched upon binding to the 
RNA.This quenching led to ready measurements of the 
stoichiometry and specificity of binding. The measured 
K, for binding of PYT to W13 is 20 nM, a value which 
represents a -200-fold increase in affinity over that 
found with tobramycin.The enhanced binding is doubt- 
less a function of the pyrene moiety, because simply 
acetylating the primary amino group of tobramycin 
does not lead to significantly enhanced binding to the 
RNA. It will be interesting to determine if the binding 
affinity of aminoglycosides in general can be enhanced 
by this kind of modification. The stoichiometry of 
binding of PYT to clone W13 RNA proved to be l:l, 
suggesting a specific mode of interaction. 
The fluorescence assay made it possible to measure the 
competition of various ligands for the aminoglycoside 
binding site directly. Tobramycin itself competed for 
binding to the aminoglycoside binding site, and its K, 
was measured to be 4.3 PM, a value close to that mea- 
sured by the equilibrium dialysis technique. 
Glucosamine did not measurably compete with PYT 
binding, showing that simple non-specific binding to 
charged amino sugars is not the basis for the observed 
binding. Erythromycin (Fig. ll), an antibiotic struc- 
turally dissimilar from tobramycin, only weakly inhib- 
ited PYT binding. By contrast, the two 
aminoglycosides, gentamycin C and in particular 
neomycin B, proved to be reasonably potent inhibitors 
of binding (Fig. 11). Interestingly, both gentamycin and 
neomycin inhibit the splicing of group I introns about 
as efficiently as does tobramycin itself [3]. In addition, 
both of these drugs also blocked the binding of acetyl 
tobramycin to E. coli ribosomes [15]. Thus it appears 
that similar structural features in RNA are recognized 
by tobramycin, gentamycin and neomycin. 
The studies reported here show that there are many 
low-affinity (-FM) solutions to the binding of the 
aminoglycoside tobramycin by RNA aptamers. From 
the selected population of low-affinity aptamers we 
Fig. 11. Antibiotics studied as competi- 
tive-binding inhibitors. 
Erythromycin A 
Gentamycin Cl Neomycin B 
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were able to isolate relatively few high-affinity (-nM) 
solutions. However, it is possible that many of the high- 
affinity aptamers were lost during the early rounds of 
selection when the copy number is low because they 
could not be eluted from the affinity column during the 
washes with 10 mM tobramycin. Molecules with high 
affinity to the column might have a very slow off rate 
and thus be less likely to bind to free tobramycin and be 
recovered in the eluant. For this reason, it is difficult to 
estimate the frequency of tight-binding aptamers in the 
initial pool with certainty. 
Approximately 1 07-1 O8 sequences capable of binding 
tobramycin with moderate affinity were found after the 
first selection. A further lo7 enrichment occurred during 
the higher stringency selection. It is not surprising, then, 
that few solutions exist for high-affinity tobramycin 
binding after the high-stringency selection. Two different 
consensus sequences were observed, as exemplified by 
Xl and J6. Secondary-structure analysis using MFOLD 
suggested that the consensus sequences in these two con- 
structs were located in stem-loop regions. Although two 
different consensus sequences were observed, they do 
show homology. In fact, the Xl and J6 stem-loop struc- 
tures could de drawn to give nearly identical loops 
(UUAGNU). The hypothesis that these putative loop 
structures contain the binding regions of the amino- 
glycosides will be tested by mutational studies and by 
chemical footprinting. 
The analysis discussed above suggests the working 
hypothesis that the binding of aminoglycoside occurs in a 
simple stem-loop or in a stem-loop with a bulge, and 
thus higher order RNA structures may be important in 
specific binding phenomena. Evidence for this notion 
comes from the independent preparation of the predicted 
stem-loop and stem-loop with a bulge regions, and the 
demonstration that these constructs bound tobramycin 
with nearly the same affinities as did the selected 
aptamers. Moreover, these stem-loop structures also 
bound two molecules of tobramycin, just like their 
aptamer precursors Xl and J6. It is interesting to note 
that the lower affinity aptamer W13 only bound one 
molecule of aminoglycoside. Whether there is a relation- 
ship between the affinity of aptamer binding to 
tobramycin and the stoichiometry of drug binding is cur- 
rently unknown. Another difference between the lower 
and higher affinity binders is found in the enhanced 
binding, relative to tobramycin, of the fluorescent deriva- 
tive PYT to the lower affinity aptamer W13. It is possible 
that the higher affinity sites are more structured than their 
low-affinity counterparts, and hence less susceptible to 
interacting with the pyrene moiety of PYT. 
Structural studies on the putative stem-loop constructs 
will determine the molecular basis for tobramycin 
recognition. Moreover, a direct structural comparison of 
the high- and low-affinity binding aptamers should 
provide important information on how to design high- 
affinity RNA-binding ligands. It will also be of interest 
to understand how two molecules of tobramycin are 
bound to the Xl and J6 stem-loops, and whether a con- 
formational change in the RNA accompanies the 
binding of the first molecule of aminoglycoside, 
enabling the second molecule to bind. 
Significance 
In this study, we found that specific RNA aptamers 
that bind the aminoglycoside antibiotic tobra- 
mycin can readily be selected from a randomized 
pool. The average K, for the pool selected under 
low stringency is in the p,M range. The RNA syn- 
thesized from an individual clone chosen at 
random bound tobramycin with a 1:l stoichiome- 
try and with about the same affinity as observed 
for the binding of tobramycin to ribosomes and 
introns. Selection at greater stringency led to the 
discovery of the highest affinity binding recorded 
for the binding of any small molecule to an RNA 
or DNA aptamer. Here clear consensus sequences, 
located in predicted stem-loop structures, were 
found. Minimal sequences predicted to form these 
stem-loop structures were synthesized and were 
capable of binding tobramycin with high affinity. 
The approaches reported here should be gener- 
ally applicable to the study of the binding of 
other aminoglycoside antibiotics and small mol- 
ecules to RNA. In particular, fluorescently labeled 
antibiotics should be useful for analyzing the 
interactions of aminoglycosides with RNA. When 
coupled with the use of high-resolution NMR 
and X-ray spectroscopic studies, it ought to be 
possible to define the specific ways in which 
RNA molecules recognize aminoglycoside anti- 
biotics.This information will be important in the 
design of novel molecules that will bind to and 
interfere with the function of specific RNA struc- 
tures. Molecules of this type could be useful as 
paradigms for the design of novel drugs. 
Materials and methods 
Reagents 
Affi-Gel 10 was purchased from Bio Rad. Tobramycin, 
neomycin trisulfate trihydrate (neomycin B > 90 %), 
ethanolamine, erythromycin, gentamycin sulfate (gentamycin C 
> 99 %), N-hydroxysuccinimide, N,N-dicyclohexylcarbodi- 
imide, 1-pyrenebutyric acid, D-gIucosamine and N,N- 
dimethylformamide were from Fluka. Amberlit CG-50, 
tetracycline and ampicillin were from Sigma. 3H-acetic anhy- 
dride was from American Radiolabeled Chemicals. o~-~~P- 
rATP and a-3sS-dATP were from New England Nuclear. 
Sephadex G-50 was from Pharmacia. The GeneAmp PCR kit, 
GeneAmp Thermostable rTth Reverse Transcriptase RNA 
PCR kit and Amplicycle Sequencing kit were from Perkin 
Elmer. The two primers used and the 109-mer random DNA 
pool were purchased from Oligos Etc., Inc. Restriction 
enzymes EcoRI and BamHI were from Boehringer Mannheim. 
pBluescript II SK(-) phagernid, XLl-Blue MRF’, E. coli host 
Specific antibiotic-RNA recognition Wang and Rando 289 
cells and the KS primer were from Stratagene. The Wizard 
Miniprep DNA Purification System was from Promega. 
Synthesis of 6-N-3H-acetyl tobramycin 
Radiolabeled acetyl tobramycin was prepared by the published 
procedure [15], but was purified by ion exchange chromatogra- 
phy (see synthesis of PYT for details of ion exchange methods) 
rather than by preparative thin layer chromatography.The R,= 
0.62 on silica (NH40H:methanol:n-butanol = 5:4:3). 
MS(FAB) = 510/(M+H)+. 
Synthesis of 6’-N-4-pyrenebutyryl tobramycin (PYT) 
I-Pyrenebutyric acid (1.0 g; 3.5 mmol) and N-hydroxysuccin- 
imide (0.40 g; 3.5 mmol) were dissolved in 40 ml dioxane.To 
this solution was added N,N-dicyclohexylcarbodiimide 
(0.72 g; 3.5 mmol).After reaction at room temperature for 4 h, 
the N-hydroxysuccinimide ester of I-pyrenebutyric acid (PYS) 
product was purified by repeated recrystallization from iso- 
propanol. Final yield = 0.87 g (65 %). TLC (silica):Rf = 0.56 
(CHCQMeOH = 2O:l). MS (EI): 385/M+. 
Tobramycin (100 mg; 0.21 mmol) and PYS (81 mg; 0.21 
mmol) were dissolved in 1.5 ml dimethylformamide (a small 
amount of H,O was added to fully dissolve tobramycin). 
After reacting at room temperature for 1 h, the reaction 
mixture was diluted with 20 n&H20, filtered, and applied to 
an Amberlit CG-50 column (5 x 120 mm).The column was 
washed with 50 ml H,O, 50 ml 0.1 M NH,OH and finally 
0.25 M NH,OH; the final elution gave the pure PYT, 40 mg 
(yield = 26 %). TLC (silica):R{ = 0.62 (H,O: methanol: 
n-butanol:NH40H = 5:4:3:1). MS (FAB): 738/(M+H)+.The 
synthesis of 6’-N-4-pyreneacetyl tobramycin was carried out 
in an identical way to the synthesis of PYT except for the 
substitution of I-pyreneacetic acid for I-pyrenebutyric acid. 
Affinity column preparation 
An N-hydroxysuccinimide Affi-Gel column was derivatized 
with either 20 kmoles or 0.075 Fmoles tobramycin per ml of 
gel to generate the affinity columns. Excess N-hydroxysuccin- 
imide linkages were blocked by adding 1 M ethanolamine.The 
resulting column served as the support for the RNA selections. 
According to data provided by the manufacturer, the number of 
reactive sites on the column was estimated as about 15 mM. 
Selections were performed in 1 ml column volumes in a buffer 
(selection buffer) containing 140 mM NaCl, 5 mM KCl, 1 n&l 
CaCJ, 1 mM M&l, and 20 mM Tris acetate at pH 7.4 [20].A 
1 ml Af&Gel IO pre-column treated with ethanolamine was 
used in all selections. 
Preparation of nucleic acid pools and selections 
The original double-stranded DNA pool was constructed by 
large scale PCR amplification of the synthesized 109-mer con- 
taining 60 random nucleotides. Sixty pg of the synthesized 60- 
mer (109 nucleotides including primers that were identical to 
those previously described [16]) containing a maximum of 
-1015 individual sequences was used for a IO-ml scale PCR 
reaction. The original RNA pool was constructed by reverse- 
transcription of 120 kg double stranded DNA. 32P-labeled 
RNA was used to follow all selections. RNA, purified by 
Sephadex G-50 column chromatography to remove unincor- 
porated nucleotides, was heated at 75 “C for 5 min, and then 
cooled down to room temperature. The RNA was then applied 
to the pre-column and washed directly onto the tobramycin 
affinity column with 1 ml of buffer. This was followed by 
washing with 20 column volumes of the buffer. Specifically 
bound RNAs were eluted with three column volumes of 
IO mM tobramycin in the selection buffer. For the first round, 
1.3 mg of RNA was used; in succeeding rounds 40-60 kg of 
RNA was used.The RNA was precipitated with ethanol, with 
glycogen as a carrier. RNA reverse transcription and PCR were 
performed in a single tube, using a GeneAmp Thermostable 
rTth Reverse Transcriptase RNA PCR kit (Perkin Elmer). 
About 50 ng of RNA template was used for 20 ~1 scale 
reverse-transcription reactions. The succeeding PCR reaction 
was done for only 4-S thermocycles to ensure high quality of 
the PCR products. Cloning of PCR DNA products was con- 
ducted using a pBluescript II SK(-) phagemid cloning vector 
and an XLl-Blue MRF’ E. coli as the host bacteria. 
Fluorescence measurements 
Steady-state fluorescence measurements were performed on a 
Perkin Elmer Model 512 double beam fluorescence spectro- 
meter. The excitation wavelength was 341 nm. All measure- 
ments were done at 20 “C in 140 mM NaCl, 5 mM KCl, 
1 mM CaC12, 1 mM MgCl, and 20 mM HEPES (pHz7.4). 
The K, of the PYT and the RNA aptarner was calculated by 
curve fitting of the fluorescence intensity as a function of 
[RNA], using the following equation (assuming a 1:l complex): 
I = I, + O.~AE([PYT]~ - (([PYTlo + [RNAIOKI)* - 4[PYTlo[RNA]Jo”) 
(Equation 1) 
where I, and I are the fluorescence intensities of PYT in the 
absence and presence of RNA, respectively, and AC is the dif- 
ference between the fluorescence intensities of 1 FM PYT in 
the presence of an infinite concentration of RNA and in its 
absence. [RNA10 is the total concentration of RNA added; 
[pYT10 is the total concentration of PYT. 
Competition binding measurements of antibiotics with RNA 
and PYT were performed at constant concentrations of PYT and 
RNA by monitoring fluorescence intensity changes as a function 
of changing concentrations of the antibiotics. The Kds for the 
antibiotics were calculated by curve fitting of the fluorescence 
intensity of PYT as a function of antibiotic concentration, using 
the following equation: 
I = lo + Ac[PYT* RNA] (Equation 2) 
where [PYT*RNA] = 0.5(([PYT], + [RNA],)([RNA], + Kd) 
+ WTI, + W’W, + %I - ((WTlo + WW,)WNAl, 
+ I$) + K,Ul, + [RNAlo + K# - 4W’JAl,, 
+ Kd)[PYT]OIRNA]O([RNA]O + Kd))o.5/([RNA]o + Kd). K, 
and K, are the dissociation constants for the antibiotic and PYT, 
respectively. [Tlo is the total concentration of antibiotic added. 
Measurements were taken at least twice for each measured K, 
Equilibrium dialysis 
Equilibrium dialysis measurements were performed by the 
published procedure [21]. 
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